Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

335.28 +3.67 (+1.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200% ↗
The company is working on a treatment for essential tremor. Positive results shocked investors following a negative readout in February. 
Via Investor's Business Daily
News headline image
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Praxis Precision Medicine's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Praxis Precision Medicines Stock Doubles - Here's Why ↗
Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key efficacy endpoints. 
Via Benzinga
News headline image
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures ↗
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures. 
Via Benzinga
News headline image
Praxis (PRAX) Q2 Loss Widens 90% ↗
Via The Motley Fool
News headline image
Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine ↗
Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market. 
Via Chartmill
News headline image
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Expert Outlook: Praxis Precision Medicine Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity ↗
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside ↗
Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine. 
Via Benzinga
News headline image
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Expert Ratings For Praxis Precision Medicine ↗
 
Via Benzinga
News headline image
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine ↗
 
Via Benzinga
News headline image
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate ↗
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025. 
Via Benzinga
News headline image
Keep an eye on the top gainers and losers in Friday's session. ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Friday's session: top gainers and losers ↗
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.